Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update
14 Agosto 2023 - 3:01PM
Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company
pioneering a novel technology for bioengineering fully
transplantable organs to help save and improve patients' lives,
today reported second quarter 2023 financial results and provided a
corporate update.
"Miromatrix remains on pace to submit a response
to the FDA’s clinical hold letter relating to our miroliverELAPtm
IND application in the second half of 2023," said Jeff Ross, Ph.D.,
Miromatrix CEO. "We continue to progress towards our goal of
gaining authorization from the FDA to initiate a Phase 1 clinical
trial to treat patients suffering from acute liver failure and
becoming the first company to treat patients with bioengineered
organs."
Business Highlights and Corporate Update
-
Confirmed plans to submit a response to the Food and Drug
Administration ("FDA") clinical hold letter pertaining to
miroliverELAP in the second half of 2023
-
Nearing completion of in-life portion of animal safety study and
biocompatibility study to address issues identified in the
miroliverELAP clinical hold letter
-
Presented three posters at 2023 American Transplant Congress
("ATC") and was awarded Best in Congress for a mirokidneytm
poster
-
Participated in National Kidney Foundation’s ("NKF") Innovation Day
congressional event
-
Participated in Association of Organ Procurement Organizations
("AOPO") annual meeting panel titled Saving Lives Through
Telepathology and Bioengineering
-
Represented cell & gene therapy sector to Capitol Hill policy
makers at Alliance for Regenerative Medicine("ARM") Congressional
Fly-In
-
Published manuscript titled “Sustained in vivo perfusion of a
re-endothelialized tissue engineered kidney graft in a human-scale
animal model,” in Frontiers in Bioengineering and
Biotechnology
-
Ended the second quarter of 2023 with $20.4 million of unrestricted
cash and investments that we believe will enable us to fund our
operations through the second quarter of
2024
Second Quarter 2023 Financial Results
Unrestricted cash and investments totaled $20.4
million as of June 30, 2023, compared to $25.6 million as of March
31, 2023. Additionally, received cash payments for
$457,143 of the $527,143 employee retention credit receivable
subsequent to the second quarter and remaining amount has been
confirmed for upcoming receipt by the Internal Revenue Service.
Operating loss was $6.7 million and $14.8
million for the three- and six-month periods ended
June 30, 2023, respectively, as compared to $8.2 million
and $15.4 million for the three- and six- month periods ended June
30, 2022, respectively. The decrease in operating loss for
comparable periods was primarily attributable to reduced research
and development lab supply costs.
Net loss was $6.5 million and $14.0 million for
the three- and six-month periods ended June 30, 2023, respectively,
as compared to $8.2 million and $15.4 million for the three- and
six- month periods ended June 30, 2022, respectively. The decrease
in net loss for comparable periods was primarily attributable to
reduced research and development lab supply costs, in addition to a
one-time employee retention credit totalling $0.5 million that was
recorded as other income in the first quarter of 2023.
Conference Call and Webcast Details
The Company will host a live conference call and
webcast to discuss these results and provide a corporate update on
Monday, August 14, 2023, at 4:30 PM ET.
To participate in the call, please dial
866-652-5200 (domestic) or 412-317-6060 (international) and provide
conference ID 10181369. The live webcast will be available on the
Events & Presentations page of the Investors section of
Miromatrix's website.
About Miromatrix
Miromatrix Medical Inc. is a life sciences
company pioneering a novel technology for bioengineering fully
transplantable human organs to help save and improve patients'
lives. The Company has developed a proprietary perfusion technology
platform for bioengineering organs that it believes will
efficiently scale to address the shortage of available human
organs. The Company's initial development focus is on human livers
and kidneys. For more information, visit miromatrix.com.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements other than statements of
historical facts are forward looking statements, including
statements regarding the potential timing of the filing of the IND
application for our MiroliverELAP product and the initiation of the
related clinical trial. In some cases, you can identify
forward-looking statements by terms such as "may," "will,"
"should," "expect," "plan," "anticipate," "could," "outlook,"
"guidance," "intend," "target," "project," "contemplate,"
"believe," "estimate," "predict," "potential," "continue,"
"remain,” or "on pace" or the negative of these terms or other
similar expressions, although not all forward-looking statements
contain these words. The forward-looking statements in this press
release are only predictions and are based largely on our current
business plans, expectations, and projections about future events
and financial trends that we believe may affect our business,
financial condition, and results of operations. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of known and unknown risks,
uncertainties and assumptions, including, but not limited to, our
history of significant losses, which we expect to continue; our
limited history operating as a commercial company; our expectations
with respect to the regulatory pathway of our product candidates,
our ability to obtain regulatory approvals for such product
candidates, and the anticipated effect of delays in obtaining any
such regulatory approvals; our expectations with respect to
preclinical and clinical trial plans for our product candidates,
the results of such activities and the safety and efficacy of our
product candidates; our ability to commercialize our product
candidates; our ability to compete successfully with larger
competitors in our highly competitive industry; our ability to
achieve and maintain adequate levels of coverage or reimbursement
for any future products we may seek to commercialize; our
expectations regarding our manufacturing capabilities; a pandemic,
epidemic or outbreak of an infectious disease in the U.S. or
worldwide, including the outbreak of the novel strain of
coronavirus, COVID-19; product liability claims; our ability to
establish and maintain intellectual property protection for our
products, as well as our ability to operate our business without
infringing the intellectual property rights of others; our ability
to attract and retain senior management and key scientific
personnel; and other important factors that could cause actual
results, performance or achievements to differ materially from
those expected or projected. For information identifying important
factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer
to the Risk Factors section of the Company's Form 10-K filed with
the U.S. Securities and Exchange Commission and any additional
risks presented in our Quarterly Reports on Form 10-Q and our
Current Reports on Form 8-K. Except as expressly required by
applicable securities law, the Company disclaims any intention or
obligation to update or revise any forward-looking statements
whether as a result of new information, future events or
otherwise.
Investor ContactGreg Chodaczek347-620-7010
ir@miromatrix.com
Media Contact:Christina
Campbell612-924-3793press@miromatrix.com
MIROMATRIX
MEDICAL INC.Condensed Balance
Sheets
|
|
|
|
|
|
|
|
|
June 30, |
|
December 31, |
|
|
2023 |
|
2022 |
|
|
(unaudited) |
|
|
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
4,571,777 |
|
|
$ |
5,208,005 |
|
Restricted cash |
|
|
800,100 |
|
|
|
800,100 |
|
Short-term investments |
|
|
15,828,281 |
|
|
|
19,989,489 |
|
Employee retention credit receivable |
|
|
527,143 |
|
|
|
— |
|
Receivable from Reprise Biomedical, Inc. |
|
|
8,517 |
|
|
|
930,355 |
|
Interest receivable |
|
|
30,707 |
|
|
|
107,861 |
|
Prepaid expenses and other current assets |
|
|
114,943 |
|
|
|
274,952 |
|
Total current assets |
|
|
21,881,468 |
|
|
|
27,310,762 |
|
Deferred offering costs |
|
|
— |
|
|
|
232,899 |
|
Right of use asset |
|
|
1,570,837 |
|
|
|
1,673,575 |
|
Property and equipment, net |
|
|
4,998,862 |
|
|
|
5,545,694 |
|
Total assets |
|
$ |
28,451,167 |
|
|
$ |
34,762,930 |
|
|
|
|
|
|
|
|
Liabilities and
Shareholders' Equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Current portion of deferred royalties |
|
$ |
739,738 |
|
|
$ |
979,167 |
|
Accounts payable |
|
|
803,571 |
|
|
|
1,584,929 |
|
Current portion of financing lease obligations |
|
|
22,506 |
|
|
|
44,157 |
|
Current portion of lease liability |
|
|
405,566 |
|
|
|
389,649 |
|
Accrued expenses |
|
|
1,916,104 |
|
|
|
1,948,376 |
|
Total current liabilities |
|
|
3,887,485 |
|
|
|
4,946,278 |
|
Deferred royalties, net |
|
|
— |
|
|
|
491,733 |
|
Long-term debt |
|
|
385,997 |
|
|
|
385,997 |
|
Financing lease obligations, net |
|
|
3,964 |
|
|
|
11,689 |
|
Lease liability, net |
|
|
2,512,062 |
|
|
|
2,720,781 |
|
Accrued interest |
|
|
113,409 |
|
|
|
99,048 |
|
Total liabilities |
|
|
6,902,917 |
|
|
|
8,655,526 |
|
Commitments and
contingencies |
|
|
|
|
|
|
Shareholders’ equity: |
|
|
|
|
|
|
Common stock, par value $0.00001; 190,000,000 shares authorized;
27,310,553 issued and outstanding as of June 30, 2023 and
20,944,109 issued and outstanding as of
December 31, 2022 |
|
|
273 |
|
|
|
209 |
|
Additional paid-in capital |
|
|
139,570,460 |
|
|
|
130,119,106 |
|
Accumulated deficit |
|
|
(118,022,483 |
) |
|
|
(104,011,911 |
) |
Total shareholders’ equity |
|
|
21,548,250 |
|
|
|
26,107,404 |
|
Total liabilities and shareholders’ equity |
|
$ |
28,451,167 |
|
|
$ |
34,762,930 |
|
|
|
|
|
|
|
|
|
|
MIROMATRIX
MEDICAL INC.Condensed Statements of
Operations(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
June 30, |
|
June 30, |
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Licensing revenue |
|
$ |
8,517 |
|
|
$ |
3,952 |
|
|
$ |
16,498 |
|
|
$ |
10,720 |
|
Cost of goods sold |
|
|
125,000 |
|
|
|
125,000 |
|
|
|
250,000 |
|
|
|
250,000 |
|
Gross loss |
|
|
(116,483 |
) |
|
|
(121,048 |
) |
|
|
(233,502 |
) |
|
|
(239,280 |
) |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
3,621,224 |
|
|
|
4,988,233 |
|
|
|
8,013,342 |
|
|
|
8,994,899 |
|
Regulatory and clinical |
|
|
397,448 |
|
|
|
419,394 |
|
|
|
803,763 |
|
|
|
774,632 |
|
Quality |
|
|
515,575 |
|
|
|
517,333 |
|
|
|
1,098,917 |
|
|
|
958,268 |
|
General and administration |
|
|
2,037,682 |
|
|
|
2,188,460 |
|
|
|
4,637,917 |
|
|
|
4,461,017 |
|
Total operating expenses |
|
|
6,571,929 |
|
|
|
8,113,420 |
|
|
|
14,553,939 |
|
|
|
15,188,816 |
|
Operating loss |
|
|
(6,688,412 |
) |
|
|
(8,234,468 |
) |
|
|
(14,787,441 |
) |
|
|
(15,428,096 |
) |
Other income (expense) |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
166,162 |
|
|
|
61,078 |
|
|
|
268,139 |
|
|
|
61,848 |
|
Interest expense |
|
|
(8,170 |
) |
|
|
(8,799 |
) |
|
|
(18,413 |
) |
|
|
(19,690 |
) |
Employee retention credit |
|
|
— |
|
|
|
— |
|
|
|
527,143 |
|
|
|
— |
|
Total other income |
|
|
157,992 |
|
|
|
52,279 |
|
|
|
776,869 |
|
|
|
42,158 |
|
Net loss |
|
$ |
(6,530,420 |
) |
|
$ |
(8,182,189 |
) |
|
$ |
(14,010,572 |
) |
|
$ |
(15,385,938 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.24 |
) |
|
$ |
(0.40 |
) |
|
$ |
(0.56 |
) |
|
$ |
(0.75 |
) |
Weighted average shares used in computing net loss per share, basic
and diluted |
|
|
27,250,573 |
|
|
|
20,615,218 |
|
|
|
24,897,796 |
|
|
|
20,547,070 |
|
MiroMatrix Medical (NASDAQ:MIRO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
MiroMatrix Medical (NASDAQ:MIRO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024